Ozempic (Semaglutide) Tablets Available Nationwide Starting May 4
Ozempic® (semaglutide) tablets will be available for the treatment of adults with type 2 diabetes (T2D) starting May…
Health Canada approves 1st generic version of Novo Nordisk’s Ozempic
Health Canada approved on Tuesday the first generic version of Danish drugmaker Novo Nordisk’s Ozempic drug. In a news…
SKF begins production of country’s first modern insulin cartridges
Bangladesh’s leading pharmaceutical company Eskayef Pharmaceuticals Limited (SKF) has begun producing modern insulin cartridges in the country for…
Novo Nordisk Expands GLP-1 Reach With Pediatric Oral Semaglutide Data
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged…
Novo Nordisk’s pill could be first oral GLP-1 RA therapy for children and adolescents with T2D
Novo Nordisk today announced positive topline results from a Phase III trial evaluating oral semaglutide for type 2…
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi
Company Logo The China Diabetes Devices Market is projected to grow from USD 7.19 billion in 2025 to…
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly’s New Treatments – News and Statistics
Apr 5, 2026 The competition between Novo Nordisk and Eli Lilly for dominance in the weight-loss medication sector…
Novo Nordisk India sets patient-centred price of Rs 202/day for starting dose of Ozempic® and Wegovy®
Novo Nordisk India sets patient-centred price of Rs 202/day for starting dose of Ozempic® and Wegovy® March 31,…
Awiqli® approved in the US, the first and
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type…
Novo Nordisk wins FDA approval for insulin injection for type 2 diabetes
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection…
Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Novo Nordisk A/S Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli®…